Search

Background: Platinum-based chemotherapy (CT) regimens have activity in triple-negative breast cancer (TNBC), with overall response rates around 50%. The evidence for activity of these regimens for hormone receptor (HR)-positive breast cancer is scarce. We aimed to evaluate the effectiveness of platinum-based CT for HR-positive HER2-negative metastatic breast cancer. Methods: We evaluated, retrospectively, electronic medical records of patients with HR-positive HER2-negative metastatic breast cancer who have received, at least, 1 dose of platinum-based CT in the metastatic setting from Jan/2015 to May/2020 in a single cancer center. Data on clinical and demographic features, treatment, and outcomes were collected. The primary study endpoint was the clinical benefit rate at 3 months. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), and prognostic factors. Results: 244 patients were included. All patients were female, with a median age of 51.5 years, 59% were premenopause, 32.8% were metastatic at diagnosis, and 63.5% had ECOG-PS 0-1 by the time of platinum-based CT initiation. Although tests for hereditary breast and ovarian cancer were not available, 41% of patients met criteria for hereditary cancer testing. Most patients had invasive ductal carcinoma (90.2%), estrogen receptor >10% positive (92.2%), and progesterone receptor >10% positive (69.7%). Main sites of metastatic disease were bone (76.2%), lymph nodes (59.4%), lung (52.9%), and liver (62.7%). The majority of patients had received previous palliative systemic therapy before platinum-based CT; 36.5% had not received previous palliative endocrine therapy (ET), and 30.7% had not received previous palliative chemotherapy. The preferred platinum-based CT regimen was cisplatin plus gemcitabine (68.8%), and a small proportion received single-agent platinum-based CT (14.3%). Forty-three patients (17.7%) started platinum-based CT during hospitalization. Grade 3-4 treatment-related toxicities occurred in 40.9% of the patients. The clinical benefit rate at 3 months was 41.2% in the overall population, 46.7% when platinum-based CT was used as first-line CT, and 38.6% when used as subsequent CT line. Overall response rate was 26.7% in first-line platinum-based CT and 18.1% in subsequent CT line. Median PFS and OS were 3.2 months (95% CI 2.8 - 3.8) and 8.6 months (95% CI 6.8 - 9.9), respectively. One-year OS rate was 37.1% (95% CI 30.5 - 43.7%). Factors associated with worse OS were ECOG-PS 3-4 (HR 1.85, 95% CI 1.21-2.82, P=0.004), presence of liver metastases (HR 1.61, 95% CI 1.16-2.23, P=0.004), and platinum-based CT initiation during hospitalization (HR 1.74, 95% CI 1.18-2.56, P=0.005). Conclusion: Despite some activity of platinum-based CT for HR-positive HER2-negative metastatic breast cancer, especially as first-line CT, response rates were lower than historically observed in TNBC. Platinum-based CT was associated with poor PFS and OS outcomes. Negative prognostic factors for OS were ECOG-PS 3-4, presence of liver metastases, and initiation of the platinum-based CT during hospitalization. Citation Format: Lucas Fernando Uratani, Francesco Sansone Bermejo, Pedro HenriqueShimiti Hashizume, Renata Colombo Bonadio, Laura Testa. Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS13-49.

Introduction Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with dismal prognosis and increasing incidence. Information on epidemiology and risk factors are scarce, particularly in Latin America. Aim Describe and analyze a multicentric cohort of CCA patients from Latin America. Methods The Ibero-Latin American Research Network on Cholangiocarcinoma (ILARN-CCA) Registry and ESCALON consortium (www.escalon.eu) collected data from patients diagnosed from 2010 and onwards. Results 183 patients with histologically/cytologically confirmed CCA were included from 5 tertiary hospitals (Brazil,Argentina,Chile,Ecuador and Peru). Median age at diagnosis was 62 years-old (IQR:25-87) and 55.7% were women. Most frequent risk factors were overweight/obesity (n=68;31.1%), diabetes (n=35;19.1%), NAFLD (n=14;7.7%), viral hepatitis (n=5;2.7%), cirrhosis (n=4;2.2%), gallstones (n=10;5.5%), primary sclerosing cholangitis (n=11;6%) and 21.3%(n=39) had no known-risk factor. Intrahepatic CCA was the predominant type (n=73;39.9%), followed by distal (n=49;26.8%) and perihilar (n=38;20.8%). Regional lymph-node invasion was found in 74 (40.4%) and metastasis in 79 (43.2%) patients. Upon diagnosis, 88 patients (48.1%) required upfront biliary stenting prior to main treatments, consisting in resection (n=39;21.3%) or palliative modalities (n=135;73.8%). Recurrence occurred in 64.1%(n=25), with median time-to-recurrence of 13.5 months (95%CI:6.5-18.8). Chemotherapy was delivered to 120 patients (Gemcitabine+Cisplatin:n=105;87.5%) with a median progression-free survival of 4.2 months (95%CI:3.4-4.9). Median overall survival of the entire cohort was 8.2 months (n=183;95%CI:6.3-10.2), 22.5 (n=39;95%CI:11.6-34.1) under surgery, 10.4 (n=87;95%CI:8.4-13.6) under chemotherapy and 2.5 (n=30;95%CI:1.5-3.9) without active treatments (log-rank p Conclusion CCA is associated to diverse etiologies in Latin-America, particularly metabolic disorders. Surgical resection shows favorable outcome, highlighting the need of surveillance strategies in individuals at risk.

Derrame pleural maligno (DPM) é um fator de mau prognóstico em pacientes com câncer de pulmão avançado. Sua patogênese ainda é pouco compreendida e as opções terapêuticas são limitadas. Modelos animais de DPM podem demonstrar novos aspectos fisiopatológicos desta doença. Stathopoulos et al. em 2006 (Am J Respir Cell Mol Biol. 2006;34:142-50) descreveram um modelo de DPM com 1,5 x105 células de LLC injetadas diretamente no espaço pleural de camundongos. Os autores relataram carcinomatose com derrame pleural, tumores pleurais e 100% de mortalidade após 17 dias. [...]